In this @-week , phase @b study , @ patients were randomized and treated with lersivirine @ mg qd ( n = @ ) , lersivirine @,@ mg qd ( n = @ ) , and etravirine @ mg bid ( n = @ ) , plus one optimized nucleoside reverse transcriptase inhibitor and darunavir/ritonavir @/@ mg bid .